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ABSTRACT 
Microspheres are solid, spherical particles of protein or polymer-based matrix which comprised of a fairly homogeneous mixture of 
polymer and active agents.It undergoes considerable presystemic metabolism (45-55%) which results in reduced bioavailability. 
Diltiazem hydrochloride was scanned in the Methanol, acid buffer, pH 1.2and phosphate buffer, pH 7.2. 10 mg of drug was 
dissolved in methanol in 100 ml in volumetric flask, and volume was made to 100 ml with same solvent. This stock solution was 
further diluted to get concentration of 10mcg/ml. This solution was scanned in UV-spectrophotometer and characteristic peak was 
observed at 239 nm for methanol, 237 nm for acid buffer, pH 1.2 and phosphate buffer, pH 7.2. Standard curve of Diltiazem 
hydrochloride was plotted in Methanol, acid buffer (pH 1.2) and phosphate buffer (pH 7.2).  The critical values for regression 
coefficient in each plot were less than 0.001 (i.e., P < 0.001).  That indicates that there was a high linear correlationbetween 
concentration of drug with absorbance. 
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INTRODUCTION 
Oral delivery of drugs is by far the most preferable route 
of drug delivery due to the ease of administration, 
patient compliance and flexibility in formulation, etc. 
1 
The frequency of administration or the dosing interval 
of any drug depends upon its half-life or mean residence 
time (MRT) and its therapeutic index. In most cases, the 
dosing interval is much shorter than the half-life of the 
drug resulting in a number of limitations.  These 
limitations can overcome by formulating into Modified-
Release dosage forms.  Modified-release products 
provide either delayed-release or extended-release of the 
drug.
2
 
There are three types of controlled drug delivery 
systems available: 
3
 
 Passive preprogrammed, in which the release rate 
is predetermined and is irresponsive to the external 
biological environment. 
 Active preprogrammed, whose release rate can be 
altered by a source external to the body (include 
most metered insulin pumps). 
 Active, self – programmed, modulate release rate of 
the drug in response to information, registered by a 
sensor, on the changing biological environment, 
such as blood sugar level in diabetes. 
Biological factors influencing design and 
performance of sustained / controlled release 
products 
3
 
 Absorption 
 Distribution 
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  Metabolism 
 Duration of Action 
 Side effects 
 Margin of safety 
 Role of disease state 
 Role of circadian rhythm 
Microspheres 
Microspheres are solid, spherical particles of protein or 
polymer based matrix which comprised of a fairly 
homogeneous mixture of polymer and active agents. 
Microspheres usually have diffusion controlled release 
profiles with a permanent release rate that is controlled 
kinetically by the particle size, whereas microcapsules 
usually have diffusion or dissolution controlled release 
profiles or both. Microcapsules expel their content by a 
single high burst as the shell breaks or slow releases.
 4, 5, 
6 
MATERIALS AND METHODS 
Drug profile: Diltiazem Hydrochloride 
Diltiazem hydrochloride is a calcium channel blocker 
(benzothiazepine), widely used for the treatment of 
angina pectoris, arrhythmias and hypertension.
 
Table 1: Parameter of Drug profile 
Description Properties Given Data 
Chemistry
7, 
8 
 
Chemical Structure 
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Chemical Name
 
(+)-cis-2,3,4,5-tetrahydro-5-(2-dimethylaminoethyl)-2- (4-
methoxyphenyl)-4-oxobenzo[b]thiazepin-3-yl acetatemonohydrochloride
 
Molecular Formula
 
C22H26N2O4S .HCl
 
Molecular Weight
 
450.98
 
Description
 
White, crystalline powder or small crystals,Odorless and has a bitter taste
 
CAS Registry Number
 
33286-22-5
 
Melting Point
 
210º C [207.5º C – 212º C] 
Optical Rotation The optical rotation of a 1% (w/v) solution of diltiazemhydrochloride in 
water at 25º C ([αD
25
]) is between +100º and +116º 
Polymorphism No polymorphs of diltiazem hydrochloride have been  reported to date 
pH pH of saturated solution in water = 3.0 
pH of 1.0% (w/w) solution in water = 4.2 
pKa 7.7 
Stability
9
 In 1N hydrochloric acid at 25ºC, 59.5% of the sample was degraded in 24 
hrs 
Pharmacoki
netics
 
Oral absorption 90% (Uniformly absorbed Throughout the GIT 
Presystemic metabolism 45-55% 
Oral bioavailability 38 ± 11% 
Plasma half life Range 2-11 h 
Mean (single dose) 4.5 h (↔ RD, Aged) (does not change with multiple dosing) 
Peak time 4.0 ± 0.4 h 
Peak concentrations 151±46ng/ml(Following a single 120mg oral dose) 
Volume of distribution 3.3 ± 1.2  liter.kg
-1
 (↔ Aged, ↓ RD) 
Plasma protein binding 80-90% 
Clearance 11.8 ± 2.2 (↔ Aged, ↓ RD) 
Metabolism Metabolized in the liver and at least six metabolites have been identified 
Urinary Excretion < 4% 
Concentration – effect 
relationship 
The minimum therapeutic plasma concentration appears to be in the range 
of  50 – 120 ng/ml 
Therapeutic Uses Stable/ Unstable angina pectoris, MI, Coronary artery spasm, 
Hypertension, Arrhythmias, Raynaud’s phenomenon, Esophageal motility 
disorders, Migraine, Primary pulmonary hypertension 
Therapeutic dose 
 
30 to 60 mg (three to four times a day).  
Loading dose = 0.25 – 0.35 mg/kg over 10 min. 
Maintenance dose = 5 – 15 mg/h  
 
Mechanism of Action:
10, 
11
 
Diltiazem is an inhibitor of calcium ion influx and causes a dose- 
dependent, inhibition of the transmembrane influx of calcium ions into 
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 into muscle via the ‘L’ channel. Diltiazem block calcium channels in 
cardiac cells at clinically used doses. 
Pharmacod
ynamic 
Parameters 
 Therapeutic Index – Wide [LD50 in male ,female mice, male, female rats : 
740, 640, 560, 610 mg/kg orally] 
Plasma drug concentration response – Good 
Physical 
Property
8,12
 
 
Solubility of Diltiazem-
HCl in various solvents 
In Chloroform, Methanol and Water: Freely soluble 
In Dehydrated alcohol: Sparingly soluble 
In Benzene: Practically insoluble. In Ether: Insoluble 
 Solubility of Diltiazem-
HCl at Various pH 
Buffer
:13
(mg/ml) ± %RSD 
HCl (1.2): 658.83 ± 4.40 
Phosphate Buffer (5.0)597.51 ± 1.54 
Phosphate Buffer (7.4)593.20 ± 3.67 
Phosphate Buffer (8.0)511.06 ± 3.94 
Category  Calcium channel blocker, Antianginal, Antihypertensive 
 
Therapeutically Beneficial Parameters 
10 
The area under the plasma concentration curve (AUC) is 
substantially higher in chronic dosing, than after a single 
dose. Therefore, following a 90mg single dose, the area 
was 505 µg liter
-1
.h
-1
, but when the same dose was given 
every 6 hour for 4 days, the AUC increased to 1216 µg 
liter
-1
.h
-1 
 Diltiazem hydrochloride is approved for clinical use 
in the United States. 
 It is not available in combination preparations.  
Preformulation Studies 
Scanning of the drug (Diltiazem hydrochloride) 
Diltiazem hydrochloride was scanned in the following 
solvent and buffers –  
i) Methanol 
ii) Acid Buffer, pH 1.2 
iii) Phosphate Buffer, pH 7.2 
i)  Scanning of the drug in solvent methanol 
10 mg of drug was dissolved in methanol in 100 ml in 
volumetric flask, and volume was made to 100 ml with 
same solvent. This stock solution was further diluted to 
get concentration of 10 mcg/ml. This solution was 
scanned in UV-spectrophotometer and characteristic 
peak was observed at 239 nm. 
ii)  Scanning of the drug in acid buffer, pH 1.2 
10 mg of drug was dissolved in acid buffer pH, 1.2 in a 
100 ml volumetric flask, and volume was made to 100 
ml with same solvent. This stock solution was further 
diluted by acid buffer to get concentration of 10 mcg/ml. 
This final solution was scanned in UV-
spectrophotometer. The characteristic peak was 
observed at 237 nm. 
iii)  Scanning of drug in phosphate buffer, pH 7.2 
10 mg of drug was dissolved in phosphate buffer pH, 7.2 
in a 100 ml volumetric flask, and volume was made to 
100 ml with same solvent. This stock solution was 
further diluted by phosphate buffer to get concentration 
of 10mcg/ml. This final solution was scanned in UV-
spectrophotometer.  The characteristic peak was 
observed at 237 nm. 
 
 
Figure 1: UV Spectrum of Diltiazem hydrochloride in solvent methanol) 
 
 
Figure 2: UV Spectrum of Diltiazem hydrochloride in acid buffer pH 1.2) 
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Table 2: Summary of the scanning of Diltiazem hydrochloride in solvent methanol and buffers 
S. 
No. 
Amount of 
Diltiazem 
Hydrochloride 
(mg) 
Solvent used to 
make up 
volume 
Final 
volume 
(ml) 
Concentration 
of stock 
solution 
(mcg/ml) 
Concentration 
of scanning 
solution 
(mcg/ml) 
Scanning 
range 
Characteristic 
peak, max (nm) 
1 10 Methanol 
 1
0
0
 
100 10 
 2
2
0
 n
m
 –
 3
0
0
 
n
m
 
239 
2 10 
Acid Buffer, 
pH 1.2 
100 10 237 
3 10 
Phosphate 
Buffer, pH 7.2 
100 
10 
 
237 
 
RESULTS 
Infrared Spectroscopy 
The IR spectrum of pure drug, Eudragit RL100, 
Eudragit RS100, Eudragit RLPO, Eudragit RSPO, 
Magnesium stearate, were recorded in potassium 
bromide using Shimadzu FTIR – 8400 S(CE).  The 
range of scanning was 500 cm
-1
 – 4000 cm-1.
 
 
Figure 3: IR Spectrum of Diltiazemhydroccloride 
 
Figure 4: IR Spectrum of Eudragit RL100 
 
Figure 5: IR Spectrum of Eudragit RS100 
 
Figure 6: IR Spectrum of Eudragit RLPO 
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Figure 7: IR Spectrum of Eudragit RSPO 
 
Figure 8: IR Spectrum of Magnesium Stearate 
 
Figure 9: IR spectrum of DTZ.HCl, F1, PF1 (Physical mixture corresponding to F1) 
 
Figure 10: IR spectrum of DTZ.HCl, F2, PF2(Physical mixture corresponding to F2) 
 
Figure 11: IR spectrum of DTZ.HCl, F3, PF3(Physical mixture corresponding to F3) 
 
Figure 12: IR spectrum of DTZ.HCl, F4, PF4(Physical mixture corresponding to F4) 
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Microspheres have received considerable attention in 
pharmaceutical and biomedical application, specifically 
achieving sustained release and controlled release 
objectives. Thus, it is an useful method for prolonging 
drug release from dosage forms, reducing adverse 
effects and to deliver drugs in a controlled manner. 
According to Biopharmaceutical Classification System 
(BCS), Diltiazem hydrochloride is having the 
characteristics of high solubility, high permeability. 
Thus it is covered under BCS class – I category. So, 
Diltiazem hydrochloride is a suitable candidate for 
sustain release formulation. 
Scanning and Standard plots of Diltiazem 
hydrochloride 
Scanning of Diltiazem hydrochloride was performed 
into Methanol, acid buffer (pH 1.2) and phosphate buffer 
(pH 7.2).  The characteristic peak, max was found to be 
at 237, 237 and 239 nm respectively. 
Standard curve of Diltiazem hydrochloride was plotted 
in Methanol, acid buffer (pH 1.2) and phosphate buffer 
(pH 7.2).  The critical values for regression co-efficient 
in each plot were less than 0.001 (i.e., P < 0.001).  That 
indicates that there was high linear correlation between 
concentrations of drug with absorbance. 
IR Spectroscopy (FTIR) 
This technique is used to determine any chemical 
interactions between drug and excipients. The Fourier 
transformed infrared (FTIR) spectra of drug, polymers, 
formulations and mixtures were obtained using FTIR 
Spectrophotometer (FTIR – 8400S (CE), SHIMADZU). 
The intermediate mixtures of drug with each polymer 
were prepared for each formulation of F1, F2, F3 and F4 
as microspheres and subjected to analysis by FTIR.  
Spectra is shown in Fig and results were tabulated 
below-
 
Table 3: Wave- number of different functional groups present in Diltiazem.HCl 
Code Composition 
Peak for Diltiazem hydrochloride 
Aromatic  
C-H 
Stretch (cm
-1
) 
O-CH3 
C-H stretch 
(cm
-1
) 
Amine HCl 
N-H stretch 
(cm
-1
) 
Acetate 
C=O stretch 
(cm
-1
) 
Lactam 
C=O stretch 
(cm
-1
) 
DTZ.HCl 
Diltiazem 
Hydrochloride 
3057.27 2837.38 2391.81 1743.71 1681.98 
F1 
PF1 
Formulation F1 
DTZ: ERL 100 
3055.35 
3057.27 
2847.03 
2839.31 
2391.81 
2389.88 
1743.71 
1745.64 
1681.98 
1681.98 
F2 
PF2 
Formulation F2 
DTZ: ERS100 
3055.35 
3057.27 
2850.88 
285088 
2389.88 
2389.88 
1743.71 
1745.64 
1681.98 
1681.98 
F3 
PF3 
Formulation F3 
DTZ: ERL PO 
3057.27 
3057.27 
2850.88 
2839.31 
2360.95 
2362.88 
1745.64 
1745.64 
1681.98 
1685.84 
F4 
Pf4 
Formulation F4 
DTZ: ERS PO 
3057.27 
3055.35 
2850.88 
2850.88 
2387.95 
2366.74 
1745.64 
1745.64 
1681.98 
1683.91 
 
Diltiazem hydrochloride is having O-CH3, Amine, 
Acetate, Lactam as functional groups.  These are the 
main sites where the chemical interaction may occur.  
After observing the spectra and above data, it could be 
concluded that the peak of these functional groups are 
intact in the intermediate mixtures and final formulations 
(Microspheres).  As there was no shifting, deleting and 
broadening of the peak observed in the spectrum, it can 
be concluded that no chemical interactions had been 
occurred.
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